Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Iadademstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oryzon Presents Iadademstat Plus Gilteritinib Data At EHA 2024
    Oryzon Presents Iadademstat Plus Gilteritinib Data At EHA 2024

    14 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/14/2898942/0/en/ORYZON-Presents-Preliminary-Data-From-Ongoing-Phase-Ib-FRIDA-Trial-with-Iadademstat-Plus-Gilteritinib-in-Relapsed-Refractory-FLT3-mut-AML-Patients-at-EHA-2024.html

    GLOBENEWSWIRE
    14 Jun 2024
    Share Share
    ORYZON's Iadademstat ALICE Phase 2a Results Published In Lancet Hematology
    ORYZON's Iadademstat ALICE Phase 2a Results Published In Lancet Hematology

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892179/0/en/ORYZON-Announces-Journal-Publication-of-Final-Phase-IIa-ALICE-Results-with-Iadademstat-in-The-Lancet-Hematology.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    ORYZON Announces FDA Clearance of Iadademstat for SCLC
    ORYZON Announces FDA Clearance of Iadademstat for SCLC

    08 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/08/2859130/0/en/ORYZON-Announces-U-S-FDA-Clearance-of-CTEP-CRADA-Phase-I-II-Clinical-Trial-Sponsored-by-NCI-for-Iadademstat-Plus-Immune-Checkpoint-Inhibitors-in-1L-Extensive-Stage-Small-Cell-Lung-.html

    GLOBENEWSWIRE
    08 Apr 2024
    Share Share
    ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat
    ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat

    15 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/15/2627578/0/en/ORYZON-Announces-First-Patient-In-in-FRIDA-a-Phase-Ib-Trial-With-Iadademstat-in-Relapsed-Refractory-FLT3-mutant-Acute-Myeloid-Leukemia-Patients.html

    GLOBENEWSWIRE
    15 Mar 2023
    Share Share
    ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat
    ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat

    16 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/16/2575422/0/en/ORYZON-Awarded-EU-Grant-to-Further-Explore-the-Role-of-Iadademstat-in-Oncological-Immunotherapy-Approaches.html

    GLOBENEWSWIRE
    16 Dec 2022
    Share Share
    ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients
    ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients

    12 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/12/12/2572191/0/en/ORYZON-Presents-Final-Data-From-Phase-IIa-ALICE-Trial-in-Unfit-AML-Patients-with-First-line-Treatment-of-Iadademstat-and-Azacitidine-in-Oral-Presentation-at-ASH-2022.html

    GLOBENEWSWIRE
    12 Dec 2022
    Share Share